Summary & Overview
HCPCS Q0169: Promethazine 12.5 mg Oral Anti‑Emetic as IV Substitute
HCPCS Level II code Q0169 designates promethazine hydrochloride 12.5 mg oral as an FDA‑approved prescription anti‑emetic used as a complete therapeutic substitute for an IV anti‑emetic during chemotherapy, limited to a 48‑hour regimen. Nationally, this code matters because it addresses a clinical need for oral alternatives at the point of chemotherapy administration, affecting site‑of‑care decisions and drug substitution policies in oncology infusion settings. Key payers in the national landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find practical context on clinical application and typical sites of service (outpatient infusion centers and oncology clinics), along with payer coverage considerations. The publication provides benchmarks and policy context relevant to reimbursement coding, utilization controls, and how payers approach oral substitution for IV anti‑emetics in chemotherapy. It also summarizes common billing practices tied to this HCPCS Level II code and highlights areas where readers may need to consult payer policies for authorization and coverage specifics. Data not available in the input for associated taxonomies, ICD‑10 diagnoses, and related service lines is noted where applicable.
Billing Code Overview
HCPCS Level II code Q0169 represents promethazine hydrochloride, 12.5 mg, oral, an FDA‑approved prescription anti‑emetic intended as a complete therapeutic substitute for an intravenous anti‑emetic during chemotherapy. The code specifies a short course use not to exceed a 48‑hour dosage regimen during the time of chemotherapy treatment.
Service Type
- Oral anti‑emetic substitute for IV anti‑emetic during chemotherapy
Typical Site of Service
- Outpatient infusion centers, oncology clinics, and other ambulatory settings where chemotherapy is administered
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology patient receiving moderately or highly emetogenic chemotherapy in an outpatient infusion center. The patient has a history of chemotherapy-induced nausea and vomiting or cannot receive an intravenous anti-emetic due to IV access issues, allergy, or patient preference. During the pre-chemotherapy assessment, the oncology nurse or pharmacist documents the anti-emetic plan. When an IV anti-emetic is withheld or a complete therapeutic substitution is required, the clinician orders oral promethazine hydrochloride Q0169 12.5 mg to be administered as an oral anti-emetic regimen not to exceed 48 hours. The medication is dispensed and administered by clinic staff or provided to the patient with clear dosing instructions; administration is recorded in the medication administration record. Typical workflow steps: patient assessment → anti-emetic order (substitution documented) → pharmacy verification and dispensing of Q0169 → administration or patient counseling for home dosing → documentation of response and adverse effects (sedation, anticholinergic effects). Typical site of service is an outpatient oncology infusion center, ambulatory infusion clinic, or hospital outpatient department, with potential use in home infusion settings when IV therapy is not suitable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 |